NVDA
NVIDIA
-- 138.850 TSLA
Tesla
-- 355.840 INTC
Intel
-- 23.600 BABA
Alibaba
-- 124.730 PLTR
Palantir
-- 119.160 
$Cassava Sciences (SAVA.US)$ Hope for Alzheimer’s Disease Su...
$Cassava Sciences (SAVA.US)$ Hope for Alzheimer’s Disease Sufferers
I believe we can see the difference in those treated with simufilam when compared to historical placebo groups. Just the visual impact comparing these groups is striking. With simufilam currently in phase 3 clinical trials, we will no doubt see a difference in AD patients (especially mild patients, who represent 60–70% of these trials) treated with simufilam vs. placebo. This is an exciting time for those struggling with AD and their family members.
Simufilam will probably be a preventive medicine for AD, so if I could, I would take it myself.’
I believe we can see the difference in those treated with simufilam when compared to historical placebo groups. Just the visual impact comparing these groups is striking. With simufilam currently in phase 3 clinical trials, we will no doubt see a difference in AD patients (especially mild patients, who represent 60–70% of these trials) treated with simufilam vs. placebo. This is an exciting time for those struggling with AD and their family members.
Simufilam will probably be a preventive medicine for AD, so if I could, I would take it myself.’
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call